Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Revenue: 2009-2025

Historic Revenue for Amicus Therapeutics (FOLD) over the last 15 years, with Sep 2025 value amounting to $169.1 million.

  • Amicus Therapeutics' Revenue rose 19.46% to $169.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $598.7 million, marking a year-over-year increase of 21.28%. This contributed to the annual value of $528.3 million for FY2024, which is 32.29% up from last year.
  • As of Q3 2025, Amicus Therapeutics' Revenue stood at $169.1 million, which was up 9.29% from $154.7 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Revenue ranged from a high of $169.1 million in Q3 2025 and a low of $66.4 million during Q1 2021.
  • For the 3-year period, Amicus Therapeutics' Revenue averaged around $125.1 million, with its median value being $125.2 million (2025).
  • Data for Amicus Therapeutics' Revenue shows a peak YoY surged of 36.73% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Amicus Therapeutics' Revenue stood at $82.2 million in 2021, then grew by 7.23% to $88.1 million in 2022, then surged by 30.63% to $115.1 million in 2023, then spiked by 30.09% to $149.7 million in 2024, then rose by 19.46% to $169.1 million in 2025.
  • Its Revenue was $169.1 million in Q3 2025, compared to $154.7 million in Q2 2025 and $125.2 million in Q1 2025.